These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs. Delves MJ Future Med Chem; 2012 Dec; 4(18):2251-63. PubMed ID: 23234549 [TBL] [Abstract][Full Text] [Related]
3. Phenotypic Screening of Small Molecules with Antimalarial Activity for Three Different Parasitic Life Stages. Kato N; March S; Bhatia SN; Marti M Methods Mol Biol; 2018; 1787():41-52. PubMed ID: 29736708 [TBL] [Abstract][Full Text] [Related]
4. Novel molecular targets for antimalarial chemotherapy. Jana S; Paliwal J Int J Antimicrob Agents; 2007 Jul; 30(1):4-10. PubMed ID: 17339102 [TBL] [Abstract][Full Text] [Related]
5. Potent Plasmodium falciparum gametocytocidal activity of diaminonaphthoquinones, lead antimalarial chemotypes identified in an antimalarial compound screen. Tanaka TQ; Guiguemde WA; Barnett DS; Maron MI; Min J; Connelly MC; Suryadevara PK; Guy RK; Williamson KC Antimicrob Agents Chemother; 2015 Mar; 59(3):1389-97. PubMed ID: 25512421 [TBL] [Abstract][Full Text] [Related]
6. Defining the biology component of the drug discovery strategy for malaria eradication. Leroy D; Campo B; Ding XC; Burrows JN; Cherbuin S Trends Parasitol; 2014 Oct; 30(10):478-90. PubMed ID: 25131411 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. Bolscher JM; Koolen KM; van Gemert GJ; van de Vegte-Bolmer MG; Bousema T; Leroy D; Sauerwein RW; Dechering KJ J Antimicrob Chemother; 2015 May; 70(5):1357-66. PubMed ID: 25667405 [TBL] [Abstract][Full Text] [Related]
10. Antimalarial drug resistance: new treatments options for Plasmodium. Gamo FJ Drug Discov Today Technol; 2014 Mar; 11():81-88. PubMed ID: 24847657 [TBL] [Abstract][Full Text] [Related]
11. 3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum. Das U; Singh RS; Alcorn J; Hickman MR; Sciotti RJ; Leed SE; Lee PJ; Roncal N; Dimmock JR Bioorg Med Chem; 2013 Dec; 21(23):7250-6. PubMed ID: 24139941 [TBL] [Abstract][Full Text] [Related]
18. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. Inoue M; Tang J; Miyakoda M; Kaneko O; Yui K; Culleton R Int J Parasitol; 2012 Aug; 42(9):859-70. PubMed ID: 22846785 [TBL] [Abstract][Full Text] [Related]
19. Primaquine treatment for Plasmodium vivax--an essential tool for malaria control and elimination in Papua New Guinea. Betuela I; Robinson LJ; Hetzel MW; Laman M; Siba PM; Bassat Q; Mueller I P N G Med J; 2014; 57(1-4):68-74. PubMed ID: 26930890 [TBL] [Abstract][Full Text] [Related]